Regulus Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview

Regulus Therapeutics

08/05/2023 13:44

* Regulus Therapeutics Inc  RGLS.OQ   RGLS.O  is expected
to show
no change in quarterly revenue when it reports  results on May
10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Regulus
Therapeutics Inc
is for a loss of 44 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $9​, above​ its last closing price of $1.41.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.51      -0.40     Beat    21.6
 Sep. 30 2022  -0.49       -0.49      -0.50     Missed  -2
 Jun. 30 2022  -0.49       -0.48      -0.50     Missed  -3.1​
 Mar. 31 2022  -0.56       -0.53      -0.50     Beat    6.2
 ​​Dec.        -0.62       -0.67      -0.70     Missed  -5
 31 2021                                                
 Sep. 30 2021  -0.76       -0.77      -1.00     Missed  -29​
 Jun. 30 2021  -0.80       -0.80      -0.80     Met     0
 Mar. 31 2021  -0.90       -0.90      -0.80     Beat    11.1
 This summary was machine generated May 8 at 12:44 GMT.  All
figures in US dollars  unless otherwise stated